How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Chain Drugstores Market
- By Store Format: Convenience Stores, Superstores, Specialty Pharmacies, Discount Stores, Hypermarkets
- By Product Category: Prescription Drugs, Over-the-Counter (OTC) Medications, Health and Wellness Products, Personal Care Products, Beauty and Cosmetics, Nutritional Supplements
- By Customer Segment: General Consumers, Senior Citizens, Chronic Disease Patients, Pediatric Patients, Women’s Health
- By Service Offering: In-store Pharmacy Services, Online Pharmacy Services, Home Delivery, Immunization Services, Health Screening Services
- By Ownership Model: Corporate-Owned Stores, Franchise Stores, Banner Stores
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Convenience Stores leads By Store Format at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 303 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.184 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.192 →
Full report · locked preview
Everything inside the Chain Drugstores Market report
A complete, evidence-based study - 12 chapters and 127 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Store Format 5
Product Category 6
Customer Segment 5
Service Offering 5
Ownership Model 3
Companies profiled
Walgreens Boots Alliance
CVS Health
Cencora (formerly McKesson Corporation)
Rite Aid Corporation
Walmart Pharmacy
Loblaw Companies Limited (Shoppers Drug Mart)
Boots UK (part of Walgreens Boots Alliance)
Walgreens Boots Alliance (International operations)
Walgreens Boots Alliance (U.S. operations)
Walgreens Boots Alliance (European operations)
Walgreens Boots Alliance (Asia operations)
Walgreens Boots Alliance (Middle East operations)
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Walgreens Boots Alliance
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →CVS Health
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Cencora (formerly McKesson Corporation)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Rite Aid Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Walmart Pharmacy
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Loblaw Companies Limited (Shoppers Drug Mart)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Boots UK (part of Walgreens Boots Alliance)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Walgreens Boots Alliance (International operations)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Walgreens Boots Alliance (U.S. operations)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Walgreens Boots Alliance (European operations)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Walgreens Boots Alliance (Asia operations)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Walgreens Boots Alliance (Middle East operations)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Walgreens Boots Alliance (Latin America operations)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Walgreens Boots Alliance (Canada operations)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Walgreens Boots Alliance (Australia operations)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,891M by 2033 · 9.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Convenience Stores45.4
- Superstores11.2
- Specialty Pharmacies17.5
- Discount Stores15.4
- Hypermarkets10.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$451.4M → $1,046M · 11.1%
Europe$314.6M → $668.0M · 9.9%
Asia Pacific$287.2M → $576.5M · 9.1%
Latin America$177.8M → $342.1M · 8.5%
Middle East and Africa$136.8M → $270.2M · 8.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.762026
9.762027
9.782028
9.802029
9.812030
9.822031
9.822032
9.842033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Walgreens Boots Alliance20.8
- CVS Health15.1
- Cencora (formerly McKesson Corporation)9.8
- Rite Aid Corporation4.9
- Walmart Pharmacy11.3
- Loblaw Companies Limited (Shoppers Drug Mart)10.1
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Store Format23.9%
Product Category20.4%
Customer Segment10.4%
Service Offering19.6%
Ownership Model25.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America36.0
- Europe23.0
- Asia Pacific19.9
- Latin America11.8
- Middle East and Africa9.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Walgreens Boots Alliance | 85 | 82 | 98 | 95 | 92 | 89 | 90 |
| CVS Health | 85 | 75 | 75 | 86 | 68 | 72 | 77 |
| Cencora (formerly McKesson Corporation) | 71 | 74 | 72 | 83 | 66 | 81 | 75 |
| Rite Aid Corporation | 80 | 68 | 78 | 63 | 60 | 75 | 71 |
| Walmart Pharmacy | 75 | 57 | 72 | 53 | 69 | 66 | 65 |
| Loblaw Companies Limited (Shoppers Drug Mart) | 71 | 69 | 57 | 54 | 55 | 53 | 60 |
| Boots UK (part of Walgreens Boots Alliance) | 60 | 49 | 42 | 57 | 49 | 61 | 53 |
| Walgreens Boots Alliance (International operations) | 54 | 57 | 50 | 40 | 37 | 38 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Walgreens Boots Alliance
- CVS Health
- Cencora (formerly McKesson Corporation)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Walgreens Boots Alliance | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| CVS Health | ✓ | − | ◐ | ◐ | ◐ | − |
| Cencora (formerly McKesson Corporation) | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Rite Aid Corporation | ◐ | − | ✓ | − | ◐ | ◐ |
| Walmart Pharmacy | ◐ | − | ◐ | − | ◐ | ◐ |
| Loblaw Companies Limited (Shoppers Drug Mart) | ◐ | − | ◐ | − | − | ◐ |
| Boots UK (part of Walgreens Boots Alliance) | − | ◐ | − | − | ◐ | − |
| Walgreens Boots Alliance (International operations) | ◐ | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Walgreens Boots Alliance90
2CVS Health77
3Cencora (formerly McKesson Corporation)75
4Rite Aid Corporation71
5Walmart Pharmacy65
6Loblaw Companies Limited (Shoppers Drug Mart)60
7Boots UK (part of Walgreens Boots Alliance)53
8Walgreens Boots Alliance (International operations)46
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Walgreens Boots Alliance
Challenger3
Strong scale, closing on the leaders.
CVS HealthCencora (formerly McKesson Corporation)Rite Aid Corporation
Contender2
Focused players with pockets of strength.
Walmart PharmacyLoblaw Companies Limited (Shoppers Drug Mart)
Niche2
Specialists in a single segment or region.
Boots UK (part of Walgreens Boots Alliance)Walgreens Boots Alliance (International operations)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Store Format in North America, then scale across Chain Drugstores Market — a $491M beachhead inside a $8.85B market.
Beachhead (SOM)$491Mobtainable near-term
Serviceable (SAM)$3.26Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Convenience Stores
Best fit — highest urgency & budget in Store Format.
Economic buyer80 fit
Superstores
Strong fit — clear ROI and a fast path to value.
End user67 fit
Specialty Pharmacies
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Store Format in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Product Category & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Customer Segment
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve22%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Store Format leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Chain Drugstores Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified22%
Evaluation12%
Closed-won5%
$10.7KCAC
$39KLTV
3.6:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Chain Drugstores Market is a resilient opportunity — $1.74B by 2033, compounding at 3.9%.
TAM · 2025$1.28Btoday
TAM · 2033$1.74Bforecast
CAGR3.9%2027–2033
Cumulative$13.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.74BTotal addressable market
SAM$683MServiceable available market
SOM$147MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.9% CAGR
Demand compounds through 2033, outpacing GDP across Store Format.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Store Format moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.74BLarge & growingTAM by 2033 at 3.9% CAGR
$683MServiceable nowreachable with today’s model
$147MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.36BBear2.6% CAGR
$1.74BBase3.9% CAGR
$2.22BBull5.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Product Category optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Chain Drugstores Market — a $5.49B market by 2033. Plan: grow share from 10.0% to 18.5%.
Market size · 2033$5.49Btotal addressable
Market CAGR3.7%2027–2033
Target share18.5%from 10.0% today
Revenue ambition$1.02Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.0% | 18.5% | On track |
| Revenue | $578M | $1.02B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 36.0% | 41.7% | On track |
| Customer retention | 88.2% | 93.1% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Store Format
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Product Category capability
A defensible second engine — invest in Product Category to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Store Format share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Product Category
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $122M capacity & capability investment
- Greenlight bolt-on M&A in Product Category
- Authorise North America expansion plan
- Fund R&D program for Store Format leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Chain Drugstores Market conversation — a $4.95B market you can size, segment and defend in minutes.
Market size · 2033$4.95Btotal opportunity
Growth7.6%CAGR to 2033
Addressable buyers1,217+accounts in scope
Typical ROI5.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Store Format
Goal Grow share in Store Format
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.9×return on cost, year one
< 3 mopayback period
$73K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Walgreens Boots AllianceCVS HealthCencora (formerly McKesson Corporation)Rite Aid CorporationWalmart PharmacyLoblaw Companies Limited (Shoppers Drug Mart)Boots UK (part of Walgreens Boots Alliance)Walgreens Boots Alliance (International operations)+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Chain Drugstores Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Chain Drugstores Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Aeromonas Aminopeptidase Recombinant Protein Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportAeromonas Aminopeptidase Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportAeromonads Diagnostic Testing Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportBusiness to Business Media Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportBusiness Resource Management Consulting Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportBilirubin Colorimeter Assay Service Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportClinical Research Organisation CRO Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportBiological Software Market
Market size, share, segmentation and regional forecast.
$585M market · 2025 base year
View reportVertical Physical Examination Service Platform Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportPublic Hospital Physical Examination Service Platform Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportAnimal Study Workflow Software Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportAerobic Systems Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.